share_log

復星醫藥：海外監管公告 - 關於對控股子公司上海復宏漢霖生物技術股份有限公司實施吸收合併及私有化的進展公告

FOSUN PHARMA: Overseas regulatory announcement - Progress announcement on the absorption merger and privatization of the holding subsidiary henlius biotechnology co., ltd.

HKEX ·  Nov 22 19:53

Summary by Moomoo AI

上海復星醫藥於2024年11月22日公告，關於控股子公司上海復宏漢霖生物技術股份有限公司的私有化及吸收合併進展。該私有化方案於2024年6月24日及8月23日獲董事會批准，計劃由復星新藥以現金及/或換股方式收購並註銷復宏漢霖的所有股份。完成後，復星新藥將承接復宏漢霖的所有資產、負債及業務。\\n本次交易已獲得中國國家發展和改革委員會於2024年11月21日的備案批准。然而，交易仍需獲得多個政府部門的審批，包括商務部、外匯管理局及相關司法管轄區的證券監管機構。此外，復宏漢霖的股東大會及H股類別股東大會需審議通過相關議案，並需香港聯交所批准其自願退市申請。\\n鑑於交易尚存不確定性，復星醫藥提醒投資者注意相關風險。交易能否最終完成，取決於多方審批及股東大會的決議結果。
上海復星醫藥於2024年11月22日公告，關於控股子公司上海復宏漢霖生物技術股份有限公司的私有化及吸收合併進展。該私有化方案於2024年6月24日及8月23日獲董事會批准，計劃由復星新藥以現金及/或換股方式收購並註銷復宏漢霖的所有股份。完成後，復星新藥將承接復宏漢霖的所有資產、負債及業務。\\n本次交易已獲得中國國家發展和改革委員會於2024年11月21日的備案批准。然而，交易仍需獲得多個政府部門的審批，包括商務部、外匯管理局及相關司法管轄區的證券監管機構。此外，復宏漢霖的股東大會及H股類別股東大會需審議通過相關議案，並需香港聯交所批准其自願退市申請。\\n鑑於交易尚存不確定性，復星醫藥提醒投資者注意相關風險。交易能否最終完成，取決於多方審批及股東大會的決議結果。
Shanghai Fosun Pharma announced on November 22, 2024, regarding the progress of the privatization and absorption merger of its holding subsidiary Henlius Biotech in Shanghai. The privatization plan was approved by the board of directors on June 24, 2024, and August 23, 2024, with Fosun Pharma planning to acquire and cancel all shares of Henlius through cash and/or stock exchange. After completion, Fosun Pharma will take over all the assets, liabilities, and business of Henlius. This transaction has been approved by the National Development and Reform Commission of China on November 21, 2024. However, the transaction still requires approval from multiple government departments, including the Ministry of Commerce, the State Administration of Foreign Exchange, and the securities regulatory institutions in relevant jurisdictions. In addition, the shareholder meetings...Show More
Shanghai Fosun Pharma announced on November 22, 2024, regarding the progress of the privatization and absorption merger of its holding subsidiary Henlius Biotech in Shanghai. The privatization plan was approved by the board of directors on June 24, 2024, and August 23, 2024, with Fosun Pharma planning to acquire and cancel all shares of Henlius through cash and/or stock exchange. After completion, Fosun Pharma will take over all the assets, liabilities, and business of Henlius. This transaction has been approved by the National Development and Reform Commission of China on November 21, 2024. However, the transaction still requires approval from multiple government departments, including the Ministry of Commerce, the State Administration of Foreign Exchange, and the securities regulatory institutions in relevant jurisdictions. In addition, the shareholder meetings of Henlius and the H-share category shareholders' meeting need to approve the relevant resolutions, and their voluntary delisting application needs approval from the Hong Kong Stock Exchange. Given the remaining uncertainties in the transaction, Fosun Pharma reminds investors to be cautious of related risks. The final completion of the transaction depends on the approvals from multiple parties and the resolutions of the shareholder meetings.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated